Elevated insulin-like growth factor binding protein (IGFBP) levels, including IGFBP-1, occur in renal failure, and may contribute towards reduced IGF bioactivity in uraemia. The reduced IGF bioactivity may, in turn, contribute towards the disturbances in protein metabolism present in renal failure. In this study, the relationships between intra-and extracellular amino acid (AA) levels and IGF-I and/or IGFBP-1 levels were studied in 30 adult patients (aged 24-70 years) on haemodialysis who had no clinical signs of malnutrition. Blood samples (n=30) and muscle biopsies (n=13) were collected for determination of free AA in erythrocytes (RBC), plasma and muscle by reverse-phase HPLC while IGFBP-1, IGF-I and insulin plasma levels were determined by radioimmunoassay.
Introduction
The growth-promoting effect of growth hormone (GH) is generally believed to be mediated through insulinlike growth factor-I (IGF-I), which acts through both endocrine and paracrine/autocrine pathways (Sara & Hall 1990) . During malnutrition and GH deficiency, the low IGF-I levels may explain the resultant growth retardation. In patients with renal failure, growth retardation and loss of body weight occur in spite of elevated fasting GH levels (Ramirez et al. 1978) and normal serum IGF-I levels (Blum et al. 1991) . However, there is a reduced bioactivity of IGF-I in uraemic serum, which may be due to increased concentrations of IGF binding proteins in the serum (Blum et al. 1991) . Six specific binding proteins with high affinity for IGFs (IGFBPs) have been characterised ( Jones & Clemmons 1995) . The majority of IGFs in serum are bound to IGFBP-3 which, together with another GH-regulated protein (acid labile subunit, ALS), forms a 150 kDa ternary complex; in this form IGFs cannot leave the circulation. The elevated serum concentrations of immunoreactive IGFBP-3 reported in uraemic patients have been attributed to an accumulation of IGFBP-3 fragments which cannot form the ternary complex, but still bind IGFs (Blum et al. 1991 . Moreover, the increase of immunoreactive IGFBP-3 fragments has been attributed to reduced fragment clearance since no increase in IGFBP-3 protease activity is found in sera from patients with renal failure (Rabkin et al. 1996) . The increased IGFBP-3 together with increased concentrations of IGFBP-1 and IGFBP-2 in uraemic patients are assumed to reduce the bioavailability of IGFs and their action at the target cells (Blum et al. 1991 , Frystyk et al. 1995 , Jones & Clemmons 1995 .
IGFBP-1 is mainly derived from the liver and counteracts the effects of IGFs in vitro. The high hepatic IGFBP-1 production rate and the rapid turnover rate in the circulation (Brismar et al. 1994 ) could give IGFBP-1 a role as regulator of the bioavailability of IGFs at the target tissue, in spite of the low serum concentration in relation to IGFBP-3. In obese subjects the free IGF-I, which is considered to be the biologically active fraction, was inversely correlated to IGFBP-1 (Frystyk et al. 1995) . Furthermore, IGFBP-1 administered to hypophysectomised rats inhibits the anabolic effects of both IGF-I and GH (Cox et al. 1994 ) and transgenic IGFBP-1 mice have retarded growth (Rajkumar et al. 1995) . In healthy subjects the IGFBP-1 levels are inversely correlated to insulin levels (Hilding et al. 1995) . While insulin appears to be the major inhibitor of IGFBP-1 , Brismar et al. 1994 , IGFBP-1 expression is stimulated by other regulators of metabolism such as glucagon (Hilding et al. 1993) . High serum IGFBP-1 levels have been found in patients with chronic renal failure (Povoa et al. 1984 , Blum et al. 1991 . In patients undergoing peritoneal dialysis, the IGFBP-1 levels have been reported to be increased in spite of high insulin levels, and the inverse relation between IGFBP-1 and insulin levels observed in healthy subjects was lost (Iglesias et al. 1996) .
A specific pattern with high concentrations of several non-essential amino acids (NEAA) and low concentrations of essential amino acids (EAA) has been reported in plasma, erythrocytes (RBC) and muscle of uraemic patients (Alvestrand et al. 1983 , Bergström et al. 1990 , Divino Filho et al. 1997 . Abnormalities in amino acid (AA) metabolism may be related to several features of chronic uraemia, such as disturbances in protein and energy metabolism and elevation of hormone levels in the circulation. The largest store of intracellular free AA is confined to the skeletal muscle (Bergström et al. 1974) . The whole blood pool represents a small fraction of the body total free AA content with higher amounts in RBC. The RBC pool of free AA is involved in the interorgan transport of AA (Elwyn et al. 1972 , Felig et al. 1973 . The effect of hormones on the kinetics of AA uptake has been reported for a large number of tissues and cell types (Shotwell et al. 1983) . The decline in plasma AA after a single injection of recombinant human IGF-I was observed to be less in dialysis patients than in controls (Fouque et al. 1995) . However, the effect of IGFs on the AA concentrations in different compartments and how IGFBP-1 may modify IGF-I-induced actions have not been clarified.
In the present study our aim has been to investigate the possibility of a link between changes in amino acid levels and the IGF-I/IGFBP-1 system in end-stage renal failure. We have therefore determined AA levels in plasma, RBC and muscle, as well as levels of serum IGFBP-1, IGF-I and insulin in a group of haemodialysis patients with no clinical signs of malnutrition.
Material and Methods

Subjects
Thirty patients (twenty-four men, six women) with a mean age of 50 years (range 24-70 years) on maintenance haemodialysis were investigated (Table 1) . Thirteen of these subjects, in whom muscle biopsies were taken, are included in another study on amino acids and uraemia (Divino Filho et al. 1997) . The causes of renal failure included chronic glomerulonephritis in 18 patients, chronic pyelonephritis in 3 patients, polycystic kidney disease in 5 patients and in 4 patients the aetiology was unknown. The patients had been on regular (thrice weekly) haemodialysis for a mean of 35 months (range 3-283 months). They were all dialysed with hollow-fibre dialysers, using a glucose-free dialysate with bicarbonate as the buffer, blood flow between 200 and 350 ml/min and dialysate flow 500 ml/min. No patient was on insulin or GH therapy. All patients were on an unrestricted diet and had stable clinical conditions, without clinical signs of malnutrition. A body mass index (BMI) value below 20 was only present in one patient (BMI=17), and his IGF-I (183 µg/l) and IGFBP-1 (95 µg/l) levels were not different from the whole group. S-albumin was measured with the bromcresol purple method and the mean value was 35·3 0·6 g/l (normal range 35-44 g/l). Eleven patients had s-albumin levels <35 g/l, without signs of wasting (BMI 22·6 1·0). The protein nitrogen appearance (PNA), which in stable patients gives an estimate of the protein intake, was calculated from urea appearance; the dialysis dose, expressed as Kt/V urea, was calculated from the dialyser urea clearance (K), dialysis time (t) and the calculated urea distribution volume (V, ml). Both were calculated according to the urea kinetic modelling method of Farrel and Gotch (1977) . These calculations were performed every 3 months. All patients had PNA >1·0 g protein/kg body weight/day and the mean Kt/V was 1·23 0·07. The nature, purpose and potential risks of the study were carefully explained to all patients before they consented to participate. Patients were studied, after an overnight fast, in the morning of a non-dialysis midweek day. Venous blood (first) and muscle samples were obtained after the subject had rested in a supine position for 30 min. Muscle samples by needle biopsy from the lateral portion of the quadriceps femoris muscle were obtained in 13 of the patients aged 24-63 years. The study protocol was approved by the Ethics Committee of the Karolinska Institute at Huddinge University Hospital.
Methods
Amino acids in plasma, RBC and muscle A heparinised blood sample was centrifuged for 10 min at 4 C in order to obtain plasma, which was then deproteinised with sulphosalicylic acid (30 mg/ml plasma) and centrifuged. The supernatant was stored at 70 C until analysis of AA. For measurement of RBC AA, white cells and platelets were carefully removed and 1 g packed red cells were rapidly haemolysed by adding 1·0 ml 1% Saponin (Sigma, St Louis, MO, USA). The sample was then extracted with 0·3 ml 50% sulphosalicyclic acid, mixed and centrifuged at 1700 g for 20 min at 4 C. The supernatant was filtered using a 0·45 µm HA filter (Millipore, Stockholm, Sweden) and frozen at 70 C until analysed (Flügel-Link et al. 1983) . Norvaline was used as the internal standard. The AA concentrations were compared with AA concentrations in plasma, muscle and RBC samples obtained from 27 healthy subjects (16 men, 11 women) with a mean age of 38·5 years (range 21-64 years) (Divino Filho et al. 1997) .
Quadriceps femoris muscle samples, obtained by needle biopsy (Bergström 1962) , were dissected free from blood and visible connective tissue, weighed repeatedly for extrapolation of the wet weight to time zero, frozen in liquid nitrogen and freeze-dried. The freeze-dried samples were weighed, fat was extracted in petroleum ether during 60 min, dried at room temperature and reweighed. The weight is referred to as fat-free solids. The sample was powdered in an agat mortar and rinsed from flakes of visible connective tissue. The powder was divided into two portions: about 2·5 mg was used for the analyses of electrolytes and about 3 mg for the determination of muscle free AA. The complete description of the technique has been described previously (Bergström 1962 ).
Free AA were determined using an automated on-line HPLC system with pre-column derivatisation (orthophthaldialdehyde/3-mercaptopropionic acid, OPA/3-MPA) and norvaline as the internal standard. The reproducibility of the method, assessed on the basis of 25 standard analyses, yielded values between 0·4% and 2·2% (coefficient of variation, CV). The error of the method was determined from 180 duplicate analyses of human plasma samples, with CV values ranging between 1·0% and 4·7% ). For calculation of intracellular AA concentrations in RBC, the water content was assumed to be 66% of RBC weight in all samples, as described by Flügel-Link et al. (1983) . The calculations of extra-and intracellular water contents and the intracellular AA concentrations in muscle based on the chloride method have been described previously (Bergström et al. 1974) .
IGF-I, IGFBP-1 and insulin
Samples for determination of IGF-I were acid-ethanol extracted and cryoprecipitated prior to the radioimmunoassay and des(1-3) IGF-I was used as the ligand to eliminate interaction of remaining IGFBPs in the samples (Bang et al. 1991) . This assay has been validated in uraemic sera, using separation by gel chromatography at low pH. The intra-and interassay CV values were 4% and 11% respectively. Since the IGF-I levels are age-dependent they were also expressed as .. scores calculated from the regression equation based on serum samples from a reference material consisting of 247 healthy men and women aged 20-70 years (Hilding et al. 1995) . Insulin was measured with a commercial assay kit (Pharmacia Insulin RIA 100, Pharmacia AB, Stockholm, Sweden). IGFBP-1 was determined using the RIA of Povoa et al. (1984) in which both phosphorylated and unphosphorylated IGFBP-1 are measured. Crossreaction was less than 0·05 for IGFBP-3 and less than 0·5% for IGFBP-2, -4, -5 and -6. The intra-and interassay CV values were 3% and 10% respectively. The relation of IGFBP-1 to insulin levels was judged by comparing the values with those obtained in a middle-aged and elderly twin population consisting of 360 subjects aged 40-80 years (Hong et al. 1996) .
Statistical analysis
Data are reported as means ... Values of IGF-I, insulin and IGFBP-1 were log transformed before analyses because the transformed values more closely approximated the Gaussian distribution. For statistical analysis of the data, the coefficient of correlation test and multiple regression analysis were used. The two-tailed unpaired Student's t-test was carried out to assess significant differences in the AA concentrations between the haemodialysis patients and a group of healthy subjects. Significant differences were set at P<0·05.
Results
The IGF-I levels in the patients on haemodialysis (geometric mean: 211 µg/l) were slightly elevated in comparison with age-matched controls. The mean IGF-I .. score was +0·74 0·30 .. and no patient had a value below 2 ... The plasma insulin levels, with a geometric mean of 10·9 µU/ml, were within the normal range. However, the geometric mean level of IGFBP-1 (89 µg/l) was significantly higher than that of age-matched controls (36 µg/l). Similar to healthy subjects, the IGFBP-1 levels were inversely correlated to insulin levels (r= 0·40, P<0·02). The slope of the regression line for log IGFBP-1 on log insulin values did not differ from that in the reference population and therefore the percentage decreases of IGFBP-1 with doubling of insulin levels were identical in the groups (Fig. 1) . However, the regression line was superimposable on the line for +2 .. of the reference material resulting in the IGFBP-1 level, in relation to insulin levels, being elevated threefold when compared with non-uraemic subjects. An inverse correlation was also found between IGFBP-1 and IGF-I levels (r= 0·50, P<0·01).
Of the EAA only leucine and valine were significantly decreased in both RBC and plasma of the patient group, and phenylalanine was significantly increased in RBC and muscle (P<0·05). Most of the NEAA in both RBC and plasma displayed higher concentrations in the patient group compared with the controls and this increase was more pronounced in RBC than in plasma (Fig. 2) . Apart from glutamate, glutamine and arginine, there were positive correlations between AA concentrations in RBC and plasma (r=0·34 to 0·77).
Mean glutamate concentration was tenfold higher in RBC (524 26 µmol/l) than in plasma (45 4 µmol/l). Plasma and RBC glutamate levels were significantly higher in the patient group than in controls (P<0·05), although no difference between the groups was observed in muscle glutamate (Table 2) . Glutamate was the only AA which displayed an inverse correlation between the concentrations in RBC and muscle (r= 0·65. P<0·02, n=12) (Fig. 3) .
The muscle glutamate levels were inversely correlated to the IGFBP-1 levels (r= 0·73, P<0·01, n=12) and positively correlated to IGF-I (r=0·64, P<0·02) (Fig. 4) as well as to the IGF-I .. score (r=0·66, P<0·02). No correlation was observed between muscle glutamate and insulin. The relationship between RBC glutamate and IGFBP-1 and/or IGF-I displayed a pattern which was opposite to that for muscle glutamate. In this group of patients, the correlation coefficient between RBC glutamate and IGFBP-1 was r=0·80 (P<0·001, n=13) and between RBC glutamate and IGF-I was r= 0·47 (P=0·10, n=13). No correlation was found between plasma and muscle glutamate levels.
In the extended group of patients (with and without muscle biopsy) a positive correlation was found between RBC glutamate and IGFBP-1 levels (r=0·51 P<0·01) (Fig. 5) and an inverse correlation with IGF-I (r= 0·46 P<0·01) (Fig. 5) , whereas no correlation was observed between RBC glutamate and insulin levels. Using the ratio between IGF-I and IGFBP-1, which has been used as an index of free IGF-I, as the independent variable, the correlation coefficient versus RBC glutamate was 0·56, indicating that 31% of the RBC glutamate variability could be attributed to this ratio. Multiple regression analyses with RBC glutamate as dependent variable and IGFBP-1 and IGF-I as independent variables gave an adjusted r 2 of 0·30 (P<0·01) with borderline significance for IGF-I (P<0·06). None of the individual plasma AA was correlated to IGF-I, IGFBP-1 or insulin levels.
Discussion
End-stage renal failure is characterised by both disturbed protein metabolism and changes in the IGF/IGFBP axis. In the present study of patients on haemodialysis, associations were found between intracellular glutamate levels and both IGF-I and IGFBP-1. Although glutamate levels in both plasma and RBC were significantly higher than in healthy subjects, only RBC glutamate correlated to the IGF-I/IGFBP-1 axis. In addition, glutamate was the only AA which displayed a significant inverse correlation between the concentration in muscle and RBC. Increased postabsorptive plasma glutamate levels have been linked to conditions with loss of body cell mass (BCM); in a recent study of 60 cancer patients an increased plasma glutamate level was attributed to a decreased capacity of peripheral muscle uptake as the uptake of glutamate and glucose over the leg were lower than in age-matched control subjects . In addition, BCM determined with impedance measurements was reported to decrease with increasing plasma glutamate levels in a longitudinal study with two healthy subjects . Whether RBC glutamate could be a better index of deranged protein metabolism than plasma glutamate has not yet been evaluated. RBC seem to have an important role in the interorgan transport of AA and blood cell elements have been implicated as important carriers in the net flux of various AA between the gut, liver and peripheral tissue in normal humans (Elwyn et al. 1972) . The finding that glutamate concentration in RBC but not plasma was inversely correlated to muscle glutamate levels in haemodialysis patients indicates that glutamate accumulates in RBC when glutamate uptake in muscle is reduced. Aoki et al. (1972) have demonstrated that RBC are important in the transport of glutamate into muscle. Insulin increases glutamate uptake into muscle (Aoki et al. 1972) . IGF-I could be expected to increase the glutamate uptake in muscle, since IGF-I stimulates glucose uptake in vitro as well as protein synthesis in vivo and reduces protein degradation (Russel-Jones & Umpleby 1996) . However, no association was found between muscle glutamate and insulin. Instead, muscle glutamate was correlated positively to IGF-I and inversely to IGFBP-1. IGFBP-1 has been shown to block the IGF-induced glucose transport into muscle in vitro (Zierath et al. 1992) . Therefore, the relationship between muscle glutamate and IGFBP-1 is proposed, at least partly, to reflect the fact that the entry of glutamate into muscle is regulated by IGF bioavailability and does not depend solely on glutamate concentration in the circulation. Although IGFBP-1 is assumed to counteract the effect of IGFs on protein metabolism in peripheral tissue, no effect is expected on the hepatic conversion of glutamine to glutamate, since hepatocytes are reported to lack IGF-I receptors. The correlations between RBC or muscle glutamate and the IGF-I/IGFBP-1 axis found in the present study do not clarify the cause. It is most likely that these variables share some common regulators although a causal relationship is not excluded. A direct stimulatory effect of glutamate or any other AA on IGFBP-1 expression in hepatocytes is unlikely, since it has been reported that withdrawal of AA from medium increased IGFBP-1 release from hepatocytes in vitro (Straus et al. 1993) . However glutamate, which is an excitatory neurotransmitter, has been reported to regulate insulin secretion via -amino-3-hydroxy-5-methyl-4-isoxazolepropilonic acid receptor, which was previously identified in isolated rat pancreas (Michalik et al. 1993 , Bertrand et al. 1995 . Nonetheless, it remains most likely that a common circulatory stimulator is present in patients on haemodialysis. Hormones with hepatic receptors such as glucagon are tentative factors. An increased hepatic extraction of glutamine and an increased release of glutamate from the liver have been reported in a patient with glucagonoma, who displayed several AA abnormalities and weight loss (Roth et al. 1987) . Future studies are required to clarify whether the increased glutamate and IGFBP-1 levels are due to increased levels of a common stimulator.
The threefold elevated IGFBP-1 levels and normal or slightly elevated IGF-I levels measured in our group of patients on haemodialysis are comparable to previous reports in patients with renal disease (Hall et al. 1988 , Jacob et al. 1990 , Sanaka et al. 1994 . It is not clear whether the high IGFBP-1 levels are due to increased production and/or delayed elimination of IGFBP-1. It has recently been reported that there is increased hepatic expression of IGFBP-1 in uraemic rats (Tönshoff et al. 1997) which suggests that there is increased IGFBP-1 production in renal failure. The absence of hyperinsulinaemia and the identical slope of the regression line of IGFBP-1 on insulin levels in comparison to controls indicate that insulin resistance is not the cause of elevated IGFBP-1 levels. Both glucagon and interleukins have to be considered as tentative stimulators of IGFBP-1 production in uraemia. Glucagon increases IGFBP-1 levels when infused into healthy subjects (Hilding et al. 1993) and hyperglucagonaemia is a common finding in chronic renal failure (Knochel 1983) . Interleukin (IL)-1, IL-6 and tumour necrosis factor alpha (TNF-) stimulate IGFBP-1 release in vitro and administration of IL-6 to mice raises their IGFBP-1 levels (Samstein et al. 1996) . Increased TNFconcentration has been reported in patients dialysed with a complement-activating membrane (Canivet et al. 1994) .
The elevated RBC NEAA and IGFBP-1 levels found in haemodialysis patients and the association between RBC glutamate and the levels of IGF-I and IGFBP-1 are similar to the pattern we have observed recently in rats kept on a protein-deficient diet ( J C Divino Filho, S J Hazel, B Anderstam, J Bergström, M Lewitt and K Hall, unpublished observations). The presence of high IGFBP-1 levels is a common finding during protein and caloric restriction but the high IGFBP-1 levels are always accompanied by low IGF-I levels ( Jones & Clemmons 1995 , Underwood 1996 . Considering that our patients had PNA >1·0 g protein/ kg body weight/day and that the IGF-I levels were within the normal range for age, it is unlikely that a reduced protein intake is the cause of the observed changes in our patients on haemodialysis. IGF-I levels have been used as indices of sufficient nutrition in dialysis patients ( Jacob et al. 1990 , Sanaka et al. 1994 . During malnutrition and fasting the high IGFBP-1 levels have been proposed to reduce the bioavailability of IGFs and thereby contribute to the catabolic condition. Furthermore, IGFBP-1 administered to hypophysectomised rats inhibits the anabolic effects of both IGF-I and GH (Cox et al. 1994 ) and transgenic IGFBP-1 mice have retarded growth (Rajkumar et al. 1995) . In this connection it could be of interest to note the correlation between lean body mass (LBM) and IGFBP-1 present in GH-deficient adult patients. LBM determined by dual energy X-ray absorptiometry was shown to be inversely related to IGFBP-1 levels, but not to IGFBP-3 levels, both before and during GH therapy, and the LBM dependency of IGFBP-1 levels was attributed to reduction of the free IGF fraction (Thoren et al. 1997) . The similarities between LBM and RBC glutamate in their relationship to IGF-I and IGFBP-1 raise the question as to whether RBC glutamate correlates to LBM and thus could be used as an indicator of LBM changes in adults.
The finding that the high RBC glutamate levels are positively correlated to the elevated serum IGFBP-1 levels in patients on haemodialysis led us to propose that changes in the bioavailability of IGFs, induced partly by IGFBP-1, are linked to the regulation of glutamate distribution in patients on haemodialysis. The cause of the threefold elevated IGFBP-1 levels in relation to insulin and the changes in intracellular glutamate levels in haemodialysis patients remains unknown.
